Geron stock stands 44.28 percent below its 52-week high

Published on 10/24/2026 at 21:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Geron held USD 327.0 million in liquidity on June 30, 2026. Geron stock costs EUR 0.99 on October 24, 2026 at 1:04 p.m. CEST.

Geron's operating picture

Geron announced oral presentations on October 12, 2026.
Cash, equivalents, restricted cash and marketable securities totaled USD 327.0 million on June 30, 2026, while first-half operating expenses fell 4 percent year over year.
Geron stock costs EUR 0.99 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.
Geron had a USD 719.6 million market capitalization on October 23, 2026.

GERN, US3741631036, Illustration mit AI erstellt.

Geron stock (ISIN US3741631036) stood 44.28 percent below its Nasdaq 52-week high of USD 2.01 on October 23, 2026, while the 52-week low was USD 1.04. Geron Corporation listed oral presentations highlighting imetelstat at international hematology congresses on October 12, 2026.

The company remains centered on RYTELO, its approved treatment for certain patients with lower-risk myelodysplastic syndromes. Geron is also studying imetelstat in myelofibrosis through a pivotal Phase 3 trial, keeping commercial execution and clinical development as separate drivers of the investment case.

Liquidity supports continued investment

Geron reported USD 327.0 million in cash, cash equivalents, restricted cash and marketable securities as of June 30, 2026. In the first half of 2026, total operating expenses declined 4 percent from the prior-year period while net revenue increased 24 percent, according to Benzinga.

Stock remains below its yearly high

The Nasdaq-listed stock was last quoted at USD 1.12 on October 23, 2026 at 4:00 p.m. ET. Its USD 1.04 to USD 2.01 52-week range puts the latest US quote 7.69 percent above the low and 44.28 percent below the high.

Valuation leaves the market cautious

Geron's market capitalization was USD 719.6 million on October 23, 2026, and its price-to-earnings ratio was negative 11.23. The company had 258 employees in its corporate profile, and RYTELO remains its commercial product while imetelstat advances in additional blood-cancer indications.

Peer comparison

Incyte (Nasdaq, USD): down 1.04 percent, price-to-earnings ratio 14.74, market capitalization USD 23.5 billion. GSK (NYSE, USD): down 0.90 percent, price-to-earnings ratio 15.92, market capitalization USD 101.7 billion.

What investors can measure next

The key operating comparison is between commercial growth and spending discipline. Geron's first-half 2026 revenue growth of 24 percent exceeded the 4 percent reduction in operating expenses, but the negative price-to-earnings ratio shows that earnings remain a separate issue for shareholders.